Could Buying AbbVie Today Set You Up for Life?

Core Viewpoint - AbbVie is positioned as a strong investment opportunity due to its solid track record, innovative product pipeline, and consistent dividend growth, making it a potential long-term wealth generator for investors [1][2]. Group 1: Performance and Track Record - AbbVie has outperformed the S&P 500 since its public debut in 2013, indicating strong financial performance [2]. - The company has successfully protected its leading drug, Humira, from biosimilars through additional patents and legal victories [3]. - AbbVie has launched new products, such as Skyrizi and Rinvoq, to sustain growth after Humira's patent expiration [3]. Group 2: Dividend Growth and Investment Potential - AbbVie is recognized as a Dividend King, having raised its dividends for over 50 consecutive years, including its time under Abbott [7]. - The company is expected to continue increasing its dividends, supported by strong product performance and growth guidance [7]. - AbbVie has a robust pipeline of products across various therapeutic areas, ensuring future growth beyond current drivers [8].